http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Stephen Lam Chan (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
First Line Treatment for Liver Cancer
( Stephen Lam Chan ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Sorafenib is the first drug treatment demonstrating survival benefits in advanced hepatocellular carcinoma (HCC). From 2008 to 2016, a number of randomized clinical trials have been conducted to test novel agents in comparison to sorafenib but none was successful. In 2017, REFLECT study demonstrated that lenvatinib, another multi-targeted tyrosine kinase inhibitor (TKI), to be non-inferior to sorafenib in the first-line setting. At the time of writing, although Lenvatinib is still under awaiting US FDA approval, many clinicians consider Lenvatinib to be reasonable alternative to Sorafenib as the first-line agent in treating advanced HCC, especially for patients at risk of hand-foot skin complica tions. Apart from TKIs, a number of phase III clinical trials have been initiated to evaluate the first-line role of check-point inhibitors. In the lecture, the current status of 1st-line treatment as well as ongoing/future direction of drug development will be presented.
-
An Unusual Cause of Hemoptysis: Congenital Absence of the Right Pulmonary Artery in a Young Male
Chan Victor Siang Hua,Ma Wai Han,Ho Wai Yin,Chan Carmen Wing Sze,Cheung Stephen Chi Wai,Lam Wendy Wai Man 아시아심장혈관영상의학회 2019 Cardiovascular Imaging Asia Vol.3 No.1
Unilateral absent pulmonary artery (UAPA) is rare and can occur in association with cardiovascular anomalies or in isolation. Herein, we describe a case of isolated UAPA in a 14-yearold male patient who presented with hemoptysis secondary to abnormal hypertrophy of collateral vasculature. The patient was successfully treated by endovascular embolization with polyvinyl alcohol particles.
-
The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
Matthew Man Pok Lee,Landon Long Chan,Stephen Lam Chan 대한간암학회 2023 대한간암학회지 Vol.23 No.2
Hepatocellular carcinoma (HCC) frequently presents as advanced stage with poor prognosis and high mortality. Systemic treatment is the treatment of choice for advanced disease. In 2007, the first multi-kinase inhibitor (MKI) sorafenib was approved and shown to modestly prolong overall survival (OS). The progress of systemic therapy has been slow afterwards until 2018 when lenvatinib, another MKI, was shown to be non-inferior to sorafenib on median OS as the first-line therapy for HCC. Since then, remarkable progress has been achieved on the treatment of advanced HCC, including the development of second-line targeted treatment, including regorafenib, cabozantinib and ramucirumab from 2017 to 2019. A growing focus has been placed on immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1), its ligand PD-L1, and cytotoxic T-lymphocyte-associated protein 4. These ICIs have proven their potency in treating HCC as both initial and subsequent line of therapy. At present, both regimens of atezolizumab combined with bevacizumab, as well as the combination of tremelimumab and durvalumab, are recommended as the first-line treatments based on positive phase III clinical trials. With the advancement of ICIs, it is anticipated that the role of MKIs in the treatment of HCC will evolve. In this article, lenvatinib, one of the most commonly used MKIs in HCC, is chosen to be reviewed.
-
Do Young Kim,Bao Nguyen Toan,Chee-Kiat Tan,Irsan Hasan,Lyana Setiawan,Ming-Lung Yu,Namiki Izumi,Nguyen Nguyen Huyen,Pierce Kah-Hoe Chow,Rosmawati Mohamed,Stephen Lam Chan,Tawesak Tanwandee,Teng-Yu Lee 대한간학회 2023 Clinical and Molecular Hepatology(대한간학회지) Vol.29 No.2
Even though the combined use of ultrasound (US) and alpha-fetoprotein (AFP) is recommended for the surveillance of hepatocellular carcinoma (HCC), the utilization of AFP has its challenges, including accuracy dependent on its cut-off levels, degree of liver necroinflammation, and etiology of liver disease. Though various studies have demonstrated the utility of protein induced by vitamin K absence II (PIVKA-II) in surveillance, treatment monitoring, and predicting recurrence, it is still not recommended as a routine biomarker test. A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and treatment monitoring of HCC, based on six predetermined statements. The experts agreed that PIVKA-II was valuable in the detection of HCC in AFP-negative patients, and could potentially benefit detection of early HCC in combination with AFP. PIVKA-II is clinically useful for monitoring curative and intra-arterial locoregional treatments, outcomes, and recurrence, and could potentially predict microvascular invasion risk and facilitate patient selection for liver transplant. However, combining PIVKA-II with US and AFP for HCC surveillance, including small HCC, still requires more evidence, whilst its role in detecting AFP-negative HCC will potentially increase as more patients are treated for hepatitis-related HCC. PIVKA-II in combination with AFP and US has a clinical role in the Asia-Pacific region for surveillance. However, implementation of PIVKA-II in the region will have some challenges, such as requiring standardization of cut-off values, its cost-effectiveness and improving awareness among healthcare providers.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
